drugset
drugset / Trial / NCT05381428

Prophylaxis of Post-ERCP Acute Pancreatitis

NCT05381428 ↗

Phase 3 Completed 184 enrolled Azienda USL Reggio Emilia - IRCCS
RandomizedParallel-groupOpen-labelPrevention

Summary

This study aims to compare indomethacin and the combination of indomethacin and aggressive lactated Ringer infusion in terms of efficacy in preventing post-ERCP acute pancreatitis (PEP).

Timeline

Start
2022-05-13
Primary completion
2024-10-12
Completion
2024-10-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Indomethacin Small molecule 100 mg Rectal
Subject Lactated Ringer Other / unclassified — Intravenous

Indications

acute pancreatitis